Research Article | Open Access
Vladimir Sorin, Patricia Ohana, Jennifer Gallula, Tatiana Birman, Imad Matouk, Ayala Hubert, Michal Gilon, Avraham Hochberg, Abraham Czerniak, "H19-Promoter-Targeted Therapy Combined with Gemcitabine in the Treatment of Pancreatic Cancer", International Scholarly Research Notices, vol. 2012, Article ID 351750, 7 pages, 2012. https://doi.org/10.5402/2012/351750
H19-Promoter-Targeted Therapy Combined with Gemcitabine in the Treatment of Pancreatic Cancer
Pancreatic cancer is the eighth cancer leading cause of cancer-related death in the world and has a 5-year survival rate of 1–4% only. Gemcitabine is a first line agent for advanced pancreatic therapy; however, its efficacy is limited by its poor intracellular metabolism and chemoresistance. Studies have been conducted in an effort to improve gemcitabine treatment results by adding other chemotherapeutic agents, but none of them showed any significant advantage over gemcitabine monotherapy. We found that 85% of human pancreatic tumors analyzed by in situ hybridization analyses showed moderated to strong expression of the H19 gene. We designed a preclinical study combining gemcitabine treatment and a DNA-based therapy for pancreatic cancer using a non viral vector BC-819 (also known as DTA-H19), expressing the diphtheria toxin A chain under the control of the H19 gene regulatory sequences. The experiments conducted either in an orthotopic and heterotopic pancreatic carcinoma animal model showed better antitumor activity following the sequential administration of the vector BC-819 and gemcitabine as compared to the effect of each of them alone. The results presented in the current study indicate that treatment with BC-819 in combination with gemcitabine might be a viable new therapeutic option for patients with advanced pancreatic cancer.
In spite of the significant progress in treatment of different kinds of cancers, pancreatic cancer still has a very low rate of 5-year survival. The majority of patients with carcinoma of pancreas have already unresectable tumor and metastatic disease at presentation. A number of studies have been conducted in an effort to improve actual treatments by combining chemotherapeutic agents and radiotherapy, but none has yet shown more than a 10 month survival result [1, 2]. Given those facts, the need for novel and effective therapies is essential.
Our group previously reported the use of a new DNA-based therapy for cancer treatment in which the plasmid BC-819 (also known as DTA-H19) drives the expression of diphtheria toxin A chain by the regulatory sequence of the H19 gene only into cancer cells [3, 4]. This therapy demonstrated good results in treatment of bladder, colon liver metastases, pancreatic and ovarian cancers [4–8]. We have shown that BC-819 injected directly into the pancreatic tumor induced a cytotoxic effect in cancer cells without affecting the surrounding normal cells. Treatment with BC-819 presents the possibilities of limiting or reversing tumor progression and even shrinking the tumor to a resectable size . The level of DTA transcript monitored by RT-PCR analyses showed the presence of DTA transcript verifying that the intratumoral injection of the plasmid leads to transfection and expression of the DTA gene . Intratumoral injections of BC-819 in a syngeneic hamster orthotopic tumor model or in subcutaneous human pancreatic tumor developed in a nude mouse model showed significant efficacy in decreasing tumor growth progression. However, it is only local therapy which may not have systemic effect. Therefore, this local control therapy should be combined with systemic chemotherapy that, probably, may improve tumor response and survival. The present work evaluates the possible advantages of local treatment of pancreatic cancer with BC-819 in combination with systemic administration of gemcitabine, the standard of care in pancreatic cancer therapy. As these two drugs induce cell growth arrest by two different mode of action, it is hypothesized that an additive effect will be observed which will force the cells to enter into apoptosis.
This work was designed to demonstrate that a combination of effective local control of the tumor with systemic therapy can improve the results of the treatment.
2. Materials and Methods
2.1. Cell Lines and Drug Solutions
The human ductal adenocarcinoma cell line CRL-1469 was obtained from the American Type Culture Collection (ATCC; Rockville, MD, USA) and cultured in 90% DMEM-F12 medium and 10% fetal bovine serum (FBS). The hamster pancreatic ductal carcinoma cell line PC.1-0 was kindly provided by Dr. Buscail L. (Institut National de la Santé et de la Recherche Médicale U531, Institut Louis Bugnard, Institut Federatif de Recherche-31, Centre Hospitalier Universitaire Rangueil, Toulouse, France) and was cultured in 90% RPMI-1640 medium supplemented with 10% FBS. Antibiotic solution penicillin (180 units/mL), streptomycin (100 μg/mL), and amphotericin-B (0.2 μg/mL) were added to all medium solution.
Gemcitabine (Eli Lilly) was diluted in saline.
2.2. Plasmids Preparation
2.3. Orthotopic Model for Pancreatic Cancer
The hamster model of pancreatic cancer was described in previous studies [7, 9], 5-6-week-old male Syrian golden hamsters (70–80 grs) were purchased from Harlan and used to generate the orthotopic model. After anesthetization by subcutaneous injection of Ketamine and Xylazine (85 mg/kg and 15 mg/kg, resp.) the pancreas was surgically exposed and hamster pancreatic carcinoma cells (PC1-0) derived from a pancreatic ductal carcinoma induced by N-nitrosobis (2-oxopropyl) amine were injected into the pancreas of 6-7-week old Syrian Golden Hamsters (). After 7 days, 100% of the animals presented a single tumor in their pancreas. The animals were randomly divided into one of the following groups: untreated control, gemcitabine alone, and BC-819 + gemcitabine; each group contained 8 animals. The control and the gemcitabine groups received 25 μL PBS by intratumoral injection, while the BC-819-treated group received 50 μg of BC-819 in a final volume of 25 μL PBS. The intratumoral injection was performed at day 7 following the injection of tumor cells. Gemcitabine (50 mg/kg) treatment was begun from day 11 and given twice weekly by intraperitoneal injection (IP). Tumor diameter measurements were taken before intratumoral treatment and before sacrifice.
Animals were then sacrificed at day 18 at which time the tumors were measured and the abdominal cavity was searched for visible metastases. Tumors were excised, weighed, and their ex vivo dimensions were recorded.
The tumor volume was calculated as , where = length and = width, using width as the smaller dimension. Tumor growth progression (TGP) was calculated according to the following formula: , where is the volume of tumor at beginning of the treatment and is volume of the same tumor at the end of the treatment.
The tumors were fixed in formalin, processed, and embedded in paraffin for pathology studies. All the tumors were histologically defined as pancreatic cancer.
2.4. Toxicity Test
The blood of 4 hamsters at each group was collected for the study of renal and liver function, blood counting (including CBC + differential, creatinine, calcium, phosphorus, urea, glucose, bilirubin, total protein, albumin, globulin, cholesterol, alkaline phosphatase, SGPT, SGOT, sodium, potassium, chloride).
2.5. Heterotopic Model for Pancreatic Cancer
In vivo local tumor growth experiments were carried out in a subcutaneous xenograft model as described in a previous study .
Confluent CRL-1469 human pancreatic carcinoma cells were injected subcutaneously into the back of athymic nude mice (5-6-week-old and 20–30 grams) purchased from Harlan (Zeist, The Netherlands). Tumor-bearing mice were randomized when tumors reached approximately 6 mm diameter. After tumor development (30 days), three BC-819 administrations were performed, with a 2-day interval between each treatment, by direct injection into the tumor at days 0, 2, and 4. Treatment consisted of 25 μg plasmid (BC-819 for treated group and 5% w/v glucose for control group) mixed with the transfectant polyethylenimine (Polyplus, Illkirsh, France) ( ratio = 6) diluted in 50 μL of 5% w/v glucose. Mice were randomly divided into one of the following groups ( per group): control (glucose 5%), BC-819 alone, gemcitabine alone, and BC-819 + gemcitabine. Animals received 2 injections of either gemcitabine (150 mg/kg) or saline by IP administration at days 37 and 41 following cells implantation.
To test survival, an additional xenograft model was used using pancreatic carcinoma cells from hamster . Confluent PC1-0 cells were trypsinized and resuspended in PBS 1. 1.5 × 105 cells in a final volume of 100 μL and were injected subcutaneously into the back of athymic nude mice (5-6-week-old and 20–30 grams). After tumor development (10 days), 3 treatments of plasmid vectors were given, with a 2-day interval between each treatment, by direct injection into the tumor. Treatment consisted of 25 μg plasmid (BC-819 for treated group and Luc-H19 reporter plasmid for control group) mixed with the transfectant polyethylenimine (Polyplus) () diluted in 50 μL of 5% w/v glucose. Mice were randomly divided into 4 groups (), including Luc-H19 (control), BC-819, Luc-H19 + gemcitabine, BC-819 + gemcitabine. Animals received either gemcitabine (150 mg/kg) or saline by IP administration at days 17 and 20 following cells implantation. Mice were sacrificed when tumor reached a diameter larger than 13 mm.
All experiments were performed according to the rules of the Animal Ethics Committee.
3.1. BC-819 Treatment in Two Different Animal Models of Pancreatic Cancer
3.1.1. Antitumor Effect following Sequential Administration of BC-819 and Gemcitabine in a Hamster Orthotopic Pancreatic Carcinoma Model
As expected, gemcitabine treatment was effective in inhibiting the tumor growth as compared to the control group. However, the sequential use of BC-819 and gemcitabine demonstrated further advantages in reducing the tumor burden (Figures 1(a) and 1(b)). The ex vivo tumor volume determined at the end of the experiment showed that compared to the control group (no treatment), the gemcitabine group was reduced by 62% while the BC-819 plus gemcitabine group displayed tumors with a size reduced by 83% (). The tumor volume in the sequential use of BC-819 and gemcitabine group was also significantly lower when compared to the gemcitabine group alone () (Figure 1(a)). Similar results were obtained measuring the tumor progression growth (TPG %) (Figure 1(b)). The control group showed 780% increment in tumor size, the gemcitabine group showed approximately 200%, while the BC-819 + gemcitabine group showed a 6% decrease in the tumor growth that is significantly lower than the gemcitabine group alone ().
Metastases occurrence was also analyzed: all animals in the control group showed multiple visible metastases at the end of the experiment, as compared to 63% of the animals treated with gemcitabine showing less than 4 metastases, and to 100% of the animals treated with BC-819 and gemcitabine showing no visible metastases (Table 1).
There was no evidence of toxicity in any treatment group based on animal appearance or weight loss. There were also no significant changes in hematology and chemistry in the BC-819 + gemcitabine treated group as compared to the untreated group.
In order to test the systemic toxicity of BC-819 given in combination with gemcitabine, several organ samples were collected from animals treated with BC-819 and gemcitabine at terminal histopathology examination. No gross or microscopic significant alterations were noted in the following organs: pancreas, liver, lung, bowel, spleen, heart, kidney, adrenal gland, lymph node, and gall bladder.
Histopathologic analysis showed that the sequential treatment with BC-819 and gemcitabine increased the necrotic area in the tumor in comparison with control groups (Figure 2).
This study demonstrated that BC-819 used in sequential use with gemcitabine is more efficient than gemcitabine alone at controlling the tumor growth progression (reflected by lower tumors volume) and at preventing the occurrence of metastases.
3.1.2. Antitumor Effect following Sequential Administration of BC-819 and Gemcitabine in a Subcutaneous Human Pancreatic Tumor in Nude Mouse Model
Local human pancreatic tumor growth experiments were carried out in a subcutaneous xenograft model. This animal model has proven useful in the measurement of tumor progression and has been reliable and reproducible.
Sequential use of BC-819 and gemcitabine resulted in a significant delay in tumor growth progression as compared to the other groups (Figure 3). The heterotopic model using CRL-1469 cells showed that 3 intratumoral injections of BC-819 alone at 2-day interval or 2 intraperitoneal administrations at 4-day interval of gemcitabine alone were able to decrease tumor growth as compared to the untreated control group; however, the combination of BC-819 and gemcitabine was significantly more effective.
A significant difference in tumor growth progression was found between the group of BC-819 + gemcitabine versus gemcitabine alone () and BC-819 alone () (Figure 3).
Both groups treated with gemcitabine alone or sequentially with BC-819 showed similar weight loss (up to 20%) as compared to the control group or the group treated with BC-819 alone (data not shown).
3.1.3. Evaluation of Survival after Sequential Administration of BC-819 and Gemcitabine in a Subcutaneous Hamster Pancreatic Tumor in Nude Mouse Model
Local tumor growth and survival experiments were carried out in a subcutaneous xenograft model.
Sequential use of BC-819 and gemcitabine resulted in a significant difference in tumor growth progression as compared to the other treatment groups (Figure 4(a)). The heterotopic model using PC-1.0 hamster pancreatic carcinoma cells also showed delay in tumor growth after administration of either BC-819 alone or Luc-H19 (control vector) + gemcitabine and further delay when the combination of BC-819 and gemcitabine was used. The inhibiting effect following the combined treatment of BC-819 and gemcitabine in the tumor growth as compared to each of the drugs alone was also more significant in the human pancreatic carcinoma xenograft.
21 days after the first treatment the survival rate in the group of mice treated with both BC-819 and gemcitabine was 100% while in the group treated with BC-819 alone was 50% and 0% in the groups treated with either the combination of gemcitabine and Luc-H19 or Luc-H19 alone (Figure 4(b)).
A significant difference in tumor growth progression was found between the group of BC-819 + gemcitabine versus Luc-H19 + gemcitabine () (Figure 4(a)).
The results show a significant increase in survival of the group treated with BC-819 + gemcitabine versus Luc-H19 + gemcitabine or BC-819 alone (Figure 4(b)).
Along with moderate differences in the tumor progression between the mice treated with BC-819 alone and those treated with the combination of BC-819 and gemcitabine, survival in the last group was also significantly longer.
The present study proposes a successful approach for the treatment of pancreatic cancer combining conventional chemotherapy used nowadays and a DNA-based therapy expressing a toxin under the control of regulatory sequences of a differentially expressed gene, the H19 gene. The human H19 gene is an imprinted gene, expressed from the maternal allele in several tissues during embryo development and repressed right after birth . H19 gene was shown to be reexpressed in several cancer tissues derived from those tissues which expressed the gene during embryonic development  such as bladder cancer , hepatocellular carcinoma , adrenocortical tumors , choriocarcinoma , colorectal cancer , ovarian carcinoma and lung carcinoma . H19 RNA shares all known characteristics of messenger RNA but has no known protein product . H19 RNA contributes significantly to several aspects of the malignant phenotype including proliferation, hypoxic stress response, angiogenesis, metastasis, and multidrug resistance [20, 21]. Cancer cells devoid of H19 expression encounter a very significant retardation of tumor growth in vivo . It was previously demonstrated that the BC-819 construct was able to kill tumor cells both in vitro and in vivo in animal models for bladder cancer, ovarian cancer, colorectal liver metastases [3–6, 8]. An expression of H19 gene in 85% of the analyzed human pancreatic cancer samples determined by in situ hybridization analysis allowed us to suggest effectiveness of the BC-819 construct in this disease. Indeed, direct intratumoral injections of BC-819 caused tumor growth retardation in pancreatic cancer animal models .
However, this treatment delaying tumor growth may not efficiently prevent metastatic spread. The combination of local therapy with systemic chemotherapeutic agent is very likely to be more effective in the control of the disease [23–26]. Thus, intraperitoneal administration of gemcitabine may inhibit metastatic spread simultaneously reducing primary tumor growth. Both BC-819 and gemcitabine display a pharmacological effect on cellular growth inhibition gemcitabine acts upstream in the cell cycle by inhibiting DNA synthesis in all cells engaged in mitosis [23–26] while BC-819 acts downstream by inhibiting protein synthesis in tumor cells exhibiting high H19 gene expression levels . As these two products induce cell growth arrest by two different mode of action, it is hypothesized that an additive effect will be observed which will force the cells to enter into apoptosis. Indeed, in both heterotopic and orthotopic pancreatic cancer animal models, intraperitoneal gemcitabine treatment affected tumor growth and reduced the number of developed metastases as compared to the control group. Nevertheless, as we suggested, the sequential use of BC-819 and gemcitabine was found significantly more effective. It provided not only delay in tumor progression, but regression of tumor size in contrast to other groups (Figures 1(a) and 1(b)). The ex vivo tumor volume in the sequential use of BC-819 and gemcitabine group was significantly lower when compared to the gemcitabine group alone () (Figure 1(a)). Our previous studies  showed that BC-819 treatment was effective in inhibiting the tumor growth compared with the Luc-H19 treated tumors; thus, excluding a nonspecific effect of the BC-819 plasmid and supporting an specific antitumor effect. The orthotopic experiment also showed that the combination of BC-819 and gemcitabine treatment affects metastasis occurrence stronger than gemcitabine alone. In contrast to the control group where all the animals showed multiple visible metastases at the end of the experiment, 63% of the animals treated with gemcitabine alone showed a few number of metastases, whereas 100% of the animals treated with BC-819 and gemcitabine did not show visible metastases at all (Table 1). Tumor invasion and metastasis are the major causes of treatment failure and death in pancreatic cancer. Therefore, the prevention of metastatic spread in animals treated with the sequential administration of BC-819 and gemcitabine indicates that the combined treatment may overcome the limitations associated with single molecule treatment that may also explain the benefit in survival rate in the heterotopic model treated with sequential administration of BC-819 and gemcitabine.
To date, some gemcitabine-containing combinations have demonstrated modest improvement when compared to gemcitabine alone, particularly in patients with good performance status [27, 28]. Delay of tumor progression, decrease in the metastatic process, and increase in the survival rate were achieved combining the systemic effect of gemcitabine with local destruction of tumor by BC-819. These findings demonstrate potential advantages of combination therapy strategies targeting multiple pathways in pancreatic cancer treatment. The rationale to use BC-819 in combination with gemcitabine in patients with locally advanced adenocarcinoma of the pancreas is thus to maximize tumor cell death. BC-819 given locally in combination with systemic chemotherapy may provide additional therapeutic benefit for the treatment of pancreatic cancer.
This work was supported by BioCancell Therapeutics Israel Ltd.
- S. Rosewicz and B. Wiedenmann, “Pancreatic carcinoma,” Lancet, vol. 349, no. 9050, pp. 485–489, 1997.
- S. E. Sanchez and J. G. Trevino, “Current adjuvant and targeted therapies for pancreatic adenocarcinoma,” Current Medicinal Chemistry, vol. 15, no. 17, pp. 1674–1683, 2008.
- P. Ohana, O. Bibi, I. Matouk et al., “Use of H19 regulatory sequences for targeted gene therapy in cancer,” International Journal of Cancer, vol. 98, no. 5, pp. 645–650, 2002.
- P. Ohana, P. Schachter, B. Ayesh et al., “Regulatory sequences of H19 and IGF2 genes in DNA-based therapy of colorectal rat liver metastases,” Journal of Gene Medicine, vol. 7, no. 3, pp. 366–374, 2005.
- A. Mizrahi, A. Czerniak, T. Levy et al., “Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences,” Journal of Translational Medicine, vol. 7, article 69, 2009.
- P. Ohana, O. N. Gofrit, S. Ayesh et al., “Regulatory sequences of the H19 gene in DNA therapy of bladder cancer,” Gene Therapy and Molecular Biology, vol. 8, pp. 181–192, 2004.
- V. Scaiewicz, V. Sorin, Y. Fellig et al., “Use of H19 gene regulatory sequences in DNA-based therapy for pancreatic cancer,” Journal of Oncology, vol. 2010, Article ID 178174, 10 pages, 2010.
- V. Sorin, P. Ohana, A. Mizrahi et al., “Regional therapy with DTA-H19 vector suppresses growth of colon adenocarcinoma metastases in the rat liver,” International Journal of Oncology, vol. 39, no. 6, pp. 1407–1412, 2011.
- H. Egami, T. Tomioka, M. Tempero, D. Kay, and P. M. Pour, “Development of intrapancreatic transplantable model of pancreatic duct adenocarcinoma in Syrian golden hamsters,” American Journal of Pathology, vol. 138, no. 3, pp. 557–561, 1991.
- C. Larbouret, B. Robert, C. Bascoul-Mollevi et al., “Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts.,” Annals of Oncology, vol. 21, no. 1, pp. 98–103, 2010.
- V. Pachnis, C. I. Brannan, and S. M. Tilghman, “The structure and expression of a novel gene activated in early mouse embryogenesis.,” EMBO Journal, vol. 7, no. 3, pp. 673–681, 1988.
- I. Ariel, S. Ayesh, and E. J. Perlman, “The product of the imprinted H19 gene is an oncofetal RNA,” Molecular Pathology, vol. 50, no. 1, pp. 34–44, 1997.
- I. Ariel, M. Sughayer, Y. Fellig et al., “The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma,” Molecular Pathology, vol. 53, no. 6, pp. 320–323, 2000.
- I. Ariel, H. Q. Miao, X. R. Ji et al., “Imprinted H19 oncofetal RNA is a candidate tumour marker for hepatocellular carcinoma,” Journal of Clinical Pathology, vol. 51, no. 1, pp. 21–25, 1998.
- Z. H. Gao, S. Suppola, J. Liu, P. Heikkilä, J. Jänne, and R. Voutilainen, “Association of H19 promoter methylation with the expression of H19 and IGF-II genes in adrenocortical tumors,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 3, pp. 1170–1176, 2002.
- O. Lustig-Yariv, E. Schulze, D. Komitowski et al., “The expression of the imprinted genes H19 and IGF-2 in choriocarcinoma cell lines. Is H19 a tumor suppressor gene?” Oncogene, vol. 15, no. 2, pp. 169–177, 1997.
- H. Cui, P. Onyango, S. Brandenburg, Y. Wu, C. L. Hsieh, and A. P. Feinberg, “Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2,” Cancer Research, vol. 62, no. 22, pp. 6442–6446, 2002.
- R. Kaplan, K. Luettich, A. Heguy, N. R. Hackett, B. G. Harvey, and R. G. Crystal, “Monoallelic up-regulation of the imprinted H19 gene in airway epithelium of phenotypically normal cigarette smokers,” Cancer Research, vol. 63, no. 7, pp. 1475–1482, 2003.
- C. I. Brannan, E. C. Dees, R. S. Ingram, and S. M. Tilghman, “The product of the H19 gene may function as an RNA,” Molecular and Cellular Biology, vol. 10, no. 1, pp. 28–36, 1990.
- I. Matouk, P. Ohana, S. Ayesh et al., “The oncofetal H19 RNA in human cancer, from the bench to the patient,” Cancer Therapy, vol. 3, pp. 249–266, 2005.
- I. Matouk, P. Ohana, E. Galun, and A. Hochberg, “The pivotal role of the oncofetal H19 RNA in human cancer, A new hope,” in Gene Therapy and Cancer Research Focus, pp. 241–260, Nova Publisher, 2008.
- I. J. Matouk, N. DeGroot, S. Mezan et al., “The H19 non-coding RNA is essential for human tumor growth,” PLoS ONE, vol. 2, no. 9, article e845, 2007.
- V. L. Damaraju, D. Y. Bouffard, C. K. W. Wong et al., “Synergistic activity of troxacitabine (Troxatyl™) and gemcitabine in pancreatic cancer,” BMC Cancer, vol. 7, article 121, 2007.
- M. Humbert, N. Castéran, S. Letard et al., “Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model,” PLoS ONE, vol. 5, no. 3, Article ID e9430, 2010.
- A. B. Kunnumakkara, S. Guha, S. Krishnan, P. Diagaradjane, J. Gelovani, and B. B. Aggarwal, “Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-κB-regulated gene products,” Cancer Research, vol. 67, no. 8, pp. 3853–3861, 2007.
- S. Réjiba, C. Bigand, C. Parmentier, and A. Hajri, “Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies,” Neoplasia, vol. 11, no. 7, pp. 637–650, 2009.
- J. D. Berlin, P. Catalano, J. P. Thomas, J. W. Kugler, D. G. Haller, and A. B. Benson, “Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297,” Journal of Clinical Oncology, vol. 20, no. 15, pp. 3270–3275, 2002.
- C. M. R. Lima, M. R. Green, R. Rotche et al., “Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate,” Journal of Clinical Oncology, vol. 22, no. 18, pp. 3776–3783, 2004.
Copyright © 2012 Vladimir Sorin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.